Skip to content.

Thallion Pharmaceuticals completes C$6.266 million sale to BELLUS Health

Date Closed

August 15, 2013

Lead Office



6.27 Million CAD

On August 15, 2013, BELLUS Health Inc. announced the consummation of the previously announced arrangement pursuant to which BELLUS Health had acquired all of the issued and outstanding common shares of Thallion Pharmaceuticals Inc. (Thallion) for a purchase price of C$6.266 million or C$0.1889 per common share, and the issuance of one contingent value right per common share. The arrangement was approved at a special meeting ot Thallion shareholders held August 6, 2013, and by the Superior Court of Québec on  August 9, 2013.

Thallion, headquartered in Laval, Quebec, is a biotechnology company developing pharmaceutical products in the areas of infectious disease and oncology.

BELLUS Health, headquartered in Laval, Quebec, is a developer of drugs for rare diseases with a particular focus on renal disorders.

McCarthy Tétrault LLP represented Thallion Pharmaceuticals, the target, with a team that was led by Patrick Boucher.